Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Women Neuroscientist Disciples of Pío del Río-Hortega: the Cajal School Spreads in Europe and South America

  • Nombela, Cristina
  • Fernández-Egea, Emilio
  • Giné, Elena
  • Worbe, Y.
  • del Río-Hortega Bereciartu, J.
  • Castro Soubriet, Fernando de
Pio del Rio-Hortega was not only the discoverer of the microglia and oligodendroglia but also possibly the most prolific mentor of all Santiago Ramon y Cajal’s disciples (Nobel awardee in Physiology or Medicine 1906 and considered as the father of modern Neuroscience). Among Río-Hortega’s mentees, three exceptional women are frequently forgotten, chronologically: Pio’s niece Asunción Amo del Río who worked with Río-Hortega at Madrid, Paris, and Oxford; the distinguished British neuropathologist Dorothy Russell who also worked with Don Pío at Oxford; and Amanda Pellegrino de Iraldi, the last mentee in his career. Our present work analyzes the figures of these three women who were in contact and collaborated with Don Pío del Río-Hortega, describing the influences received and the impact on their careers and the History of Neuroscience. The present work completes the contribution of women neuroscientists who worked with Cajal and his main disciples of the Spanish Neurological School both in Spain (previous work) and in other countries (present work)., The research group of FdC was currently supported by the Spanish Ministerio de Ciencia e Investigación [grant nos. PID2019-109858RB-100, RD16-0015-0019 (partially financed by F.E.D.E.R.: European Union “Una manera de hacer Europa”), and EIN2020-112366], Consejo Superior de Investigaciones Científicas-CSIC/Spanish Research Council (grant nos. 2019AEP033 and LINKA20268), the Fundación Ramón Areces (Spain, grant no. CIVP19A5917), the Comunidad de Madrid (Spain, grant no. IND2018/BMD-9751), and a grant from the Federation of European Neuroscience Societies (FENS) History Online Project Grants Call 2018. CN received funding from RTI2018-097838-B-I00, granted by the Spanish Ministerio de Ciencia e Innovación (PI: Prof. Eduardo Demetrio Crespo).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

  • Calvo-Barreiro, Laura|||0000-0002-8524-3305
  • Eixarch, Herena|||0000-0001-7525-9533
  • Ponce-Alonso, Manuel|||0000-0002-3239-9373
  • Castillo Juárez, Mireia|||0000-0001-8979-3219
  • Lebrón-Galán, Rafael
  • Mestre, Leyre|||0000-0001-6970-2316
  • Clemente, Diego|||0000-0003-4829-9497
  • del Campo, Rosa|||0000-0003-1147-7923
  • Montalban, Xavier|||0000-0002-0098-9918
  • Espejo, Carmen|||0000-0001-9949-5901
Previous studies in experimental autoimmune encephalomyelitis (EAE) models have shown that some probiotic bacteria beneficially impact the development of this experimental disease. Here, we tested the therapeutic effect of two commercial multispecies probiotics-Lactibiane iki and Vivomixx-on the clinical outcome of established EAE. Lactibiane iki improves EAE clinical outcome in a dose-dependent manner and decreases central nervous system (CNS) demyelination and inflammation. This clinical improvement is related to the inhibition of pro-inflammatory and the stimulation of immunoregulatory mechanisms in the periphery. Moreover, both probiotics modulate the number and phenotype of dendritic cells (DCs). Specifically, Lactibiane iki promotes an immature, tolerogenic phenotype of DCs that can directly induce immune tolerance in the periphery, while Vivomixx decreases the percentage of DCs expressing co-stimulatory molecules. Finally, gut microbiome analysis reveals an altered microbiome composition related to clinical condition and disease progression. This is the first preclinical assay that demonstrates that a commercial probiotic performs a beneficial and dose-dependent effect in EAE mice and one of the few that demonstrates a therapeutic effect once the experimental disease is established. Because this probiotic is already available for clinical trials, further studies are being planned to explore its therapeutic potential in multiple sclerosis patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

  • Camacho-Toledano, Celia
  • Machín-Díaz, Isabel
  • Calahorra, Leticia
  • Cabañas-Cotillas, María
  • Otaegui, David|||0000-0002-6625-5976
  • Castillo-Triviño, Tamara|||0000-0002-9249-3185
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Midaglia, Luciana|||0000-0001-7981-2228
  • García Domínguez, José Manuel
  • García-Arocha, Jennifer
  • Ortega, María Cristina
  • Clemente, Diego|||0000-0003-4829-9497
The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the sphingosine-1-phosphate receptor modulators. In addition to inhibiting T cell egress from lymph nodes, fingolimod promotes the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs), whose monocytic subset (M-MDSCs) can be used as a biomarker of disease severity, as well as the degree of demyelination and extent of axonal damage in the experimental autoimmune encephalomyelitis (EAE) model of MS. In the present study, we have assessed whether the abundance of circulating M-MDSCs may represent a useful biomarker of fingolimod efficacy in EAE and in the clinical context of MS patients. Treatment with vehicle or fingolimod was orally administered to EAE mice for 14 days in an individualized manner, starting the day when each mouse began to develop clinical signs. Peripheral blood from EAE mice was collected previous to treatment and human peripheral blood mononuclear cells (PBMCs) were collected from fingolimod to treat MS patients' peripheral blood. In both cases, M-MDSCs abundance was analyzed by flow cytometry and its relationship with the future clinical affectation of each individual animal or patient was assessed. Fingolimod-treated animals presented a milder EAE course with less demyelination and axonal damage, although a few animals did not respond well to treatment and they invariably had fewer M-MDSCs prior to initiating the treatment. Remarkably, M-MDSC abundance was also found to be an important and specific parameter to distinguish EAE mice prone to better fingolimod efficacy. Finally, in a translational effort, M-MDSCs were quantified in MS patients at baseline and correlated with different clinical parameters after 12 months of fingolimod treatment. M-MDSCs at baseline were highly representative of a good therapeutic response to fingolimod, i.e., patients who met at least two of the criteria used to define non-evidence of disease activity-3 (NEDA-3) 12 months after treatment. Our data indicate that M-MDSCs might be a useful predictive biomarker of the response of MS patients to fingolimod. The online version contains supplementary material available at 10.1186/s12974-022-02635-3.